Literature DB >> 16405547

Risk factors for post-ERCP pancreatitis: a prospective multicenter study.

Chi-Liang Cheng1, Stuart Sherman, James L Watkins, Jeffrey Barnett, Martin Freeman, Joseph Geenen, Michael Ryan, Harrison Parker, James T Frakes, Evan L Fogel, William B Silverman, Kulwinder S Dua, Giuseppe Aliperti, Paul Yakshe, Michael Uzer, Whitney Jones, John Goff, Laura Lazzell-Pannell, Abdullah Rashdan, M'hamed Temkit, Glen A Lehman.   

Abstract

OBJECTIVES: Pancreatitis is the most common and serious complication of diagnostic and therapeutic ERCP. The aim of this study is to examine the potential patient- and procedure-related risk factors for post-ERCP pancreatitis in a prospective multicenter study.
METHODS: A 160-variable database was prospectively collected by a defined protocol on patients undergoing diagnostic or therapeutic ERCP at 15 centers in the Midwest Pancreaticobiliary Group and participating in a randomized controlled study evaluating whether prophylactic corticosteroids will reduce the incidence of post-ERCP pancreatitis. Data were collected prior to the procedure, at the time of procedure, and 24-72 h after discharge. Post-ERCP pancreatitis was diagnosed and its severity graded according to consensus criteria.
RESULTS: Of the 1,115 patients enrolled, diagnostic ERCP with or without sphincter of Oddi manometry (SOM) was performed in 536 (48.1%) and therapeutic ERCP in 579 (51.9%). Suspected sphincter of Oddi dysfunction (SOD) was the indication for the ERCP in 378 patients (33.9%). Pancreatitis developed in 168 patients (15.1%) and was graded mild in 112 (10%), moderate in 45 (4%), and severe in 11(1%). There was no difference in the incidence of pancreatitis or the frequency of investigated potential pancreatitis risk factors between the corticosteroid and placebo groups. By univariate analysis, the incidence of post-ERCP pancreatitis was significantly higher in 19 of 30 investigated variables. In the multivariate risk model, significant risk factors with adjusted odds ratios (OR) were: minor papilla sphincterotomy (OR: 3.8), suspected SOD (OR: 2.6), history of post-ERCP pancreatitis (OR: 2.0), age <60 yr (OR: 1.6), > or =2 contrast injections into the pancreatic duct (OR: 1.5), and trainee involvement (OR: 1.5). Female gender, history of recurrent idiopathic pancreatitis, pancreas divisum, SOM, difficult cannulation, and major papilla sphincterotomy (either biliary or pancreatic) were not multivariate risk factors for post-ERCP pancreatitis.
CONCLUSION: This study emphasizes the role of patient factors (age, SOD, prior history of post-ERCP pancreatitis) and technical factors (number of PD injections, minor papilla sphincterotomy, and operator experience) as the determining high-risk predictors for post-ERCP pancreatitis.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16405547     DOI: 10.1111/j.1572-0241.2006.00380.x

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  151 in total

1.  Dietary approaches following endoscopic retrograde cholangiopancreatography: A survey of selected endoscopists.

Authors:  Lincoln Evvc Ferreira; Mark D Topazian; William S Harmsen; Alan R Zinsmeister; Todd H Baron
Journal:  World J Gastrointest Endosc       Date:  2010-12-16

2.  Management of pancreas divisum.

Authors:  J Steven Burdick; Edward Horvath
Journal:  Curr Treat Options Gastroenterol       Date:  2006-09

3.  The impact of prophylactic pancreatic stenting on post-ERCP pancreatitis: A nationwide, register-based study.

Authors:  Greger Olsson; Jeanne Lübbe; Urban Arnelo; Eduard Jonas; Björn Törnqvist; Lars Lundell; Lars Enochsson
Journal:  United European Gastroenterol J       Date:  2016-07-08       Impact factor: 4.623

4.  Severe and fatal complications after ERCP: analysis of 2555 procedures in a single experienced center.

Authors:  P Salminen; S Laine; R Gullichsen
Journal:  Surg Endosc       Date:  2007-12-20       Impact factor: 4.584

5.  Transnasal endoscopic retrograde chalangiopancreatography using an ultrathin endoscope: a prospective comparison with a routine oral procedure.

Authors:  Akihiro Mori; Noritsugu Ohashi; Takako Maruyama; Hideharu Tatebe; Katsuhisa Sakai; Takashi Shibuya; Hiroshi Inoue; Shoudou Takegoshi; Masataka Okuno
Journal:  World J Gastroenterol       Date:  2008-03-14       Impact factor: 5.742

6.  The results of the Tokyo trial of prevention of post-ERCP pancreatitis with risperidone (Tokyo P3R): a multicenter, randomized, phase II, non-placebo-controlled trial.

Authors:  Takeshi Tsujino; Hiroyuki Isayama; Yousuke Nakai; Yukiko Ito; Osamu Togawa; Nobuo Toda; Toshihiko Arizumi; Hirofumi Kogure; Keisuke Yamamoto; Suguru Mizuno; Yoko Yashima; Hiroshi Yagioka; Takashi Sasaki; Saburo Matsubara; Natsuyo Yamamoto; Kenji Hirano; Naoki Sasahira; Minoru Tada; Kazuhiko Koike
Journal:  J Gastroenterol       Date:  2012-10-24       Impact factor: 7.527

Review 7.  Balloon dilation itself may not be a major determinant of post-endoscopic retrograde cholangiopancreatography pancreatitis.

Authors:  Sung Ill Jang; Gak Won Yun; Dong Ki Lee
Journal:  World J Gastroenterol       Date:  2014-12-07       Impact factor: 5.742

8.  Prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis by pancreatic duct stenting using a loop-tipped guidewire.

Authors:  Yuji Sakai; Toshio Tsuyuguchi; Harutoshi Sugiyama; Masahiro Hayashi; Jun-Ichi Senoo; Reina Sasaki; Yuko Kusakabe; Masato Nakamura; Shin Yasui; Rintaro Mikata; Masaru Miyazaki; Osamu Yokosuka
Journal:  World J Clin Cases       Date:  2016-08-16       Impact factor: 1.337

9.  Refinement of canine pancreatitis model: inducing pancreatitis by using endoscopic retrograde cholangiopancreatography.

Authors:  Dawn S Ruben; Diana G Scorpio; K L Gabrielson; B W Simon; Jonathan M Buscaglia
Journal:  Comp Med       Date:  2009-02       Impact factor: 0.982

10.  Risk models for post-endoscopic retrograde cholangiopancreatography pancreatitis (PEP): smoking and chronic liver disease are predictors of protection against PEP.

Authors:  Matthew J DiMagno; Joshua P Spaete; Darren D Ballard; Erik-Jan Wamsteker; Sameer D Saini
Journal:  Pancreas       Date:  2013-08       Impact factor: 3.327

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.